PMID- 20139227
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20181204
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 138
IP  - 1
DP  - 2010 Jul
TI  - Fluorescence in situ hybridization in the definitive diagnosis of malignant 
      mesothelioma in effusion cytology.
PG  - 137-44
LID - 10.1378/chest.09-1951 [doi]
AB  - BACKGROUND: Distinction of malignant mesothelioma (MM) from reactive mesothelial 
      cells (RM) in effusions is notoriously difficult. The aim of our study was to 
      test chromosomal aberrations detected by fluorescence in situ hybridization 
      (FISH) in the diagnosis of MM in effusion cytology and to explore the potential 
      role of p16, p14, and p15 gene methylation as an alternative mechanism of tumor 
      suppressor gene inactivation. METHODS: Fifty-two effusions of biopsy-proven MM 
      and 28 benign effusions were retrospectively analyzed by multitarget FISH assay 
      for aberrations of chromosomes 3, 7, 17, and 9p21. In case of a negative result, 
      the corresponding MM biopsy specimen was analyzed. Methylation-specific 
      polymerase chain reaction (MSP) for p16, p14, and p15 was performed on 
      FISH-negative MM biopsy specimens. RESULTS: Seventy-nine percent of effusions 
      with biopsy-proven MM had chromosomal aberrations, with loss of 9p21 as the most 
      common finding. All benign effusions were FISH negative. Sensitivity, 
      specificity, and positive and negative predictive values for detection of MM by 
      FISH were 79%, 100%, 100%, and 72%, respectively. Six of nine FISH-negative 
      effusions with biopsy-proven MM were also FISH negative in the MM biopsy 
      specimens. Four of five FISH-negative biopsy specimens showed promoter 
      methylation in p16 and p14 as compared with one of 12 benign controls. 
      CONCLUSIONS: FISH is a sensitive and highly specific method for the definitive 
      diagnosis of MM in effusion cytology. In the subset of FISH-negative MM, tumor 
      suppressor genes on the chromosomal region 9p21 are often inactivated by promoter 
      methylation.
FAU - Savic, Spasenija
AU  - Savic S
AD  - Institute for Pathology, University Hospital Basel, Schonbeinstrasse 40, 4031 
      Basel, Switzerland. ssavic@uhbs.ch
FAU - Franco, Noreli
AU  - Franco N
FAU - Grilli, Bruno
AU  - Grilli B
FAU - Barascud, Audrey de Vito
AU  - Barascud Ade V
FAU - Herzog, Michelle
AU  - Herzog M
FAU - Bode, Beata
AU  - Bode B
FAU - Loosli, Heinz
AU  - Loosli H
FAU - Spieler, Peter
AU  - Spieler P
FAU - Schonegg, Rene
AU  - Schonegg R
FAU - Zlobec, Inti
AU  - Zlobec I
FAU - Clark, Douglas P
AU  - Clark DP
FAU - Herman, James G
AU  - Herman JG
FAU - Bubendorf, Lukas
AU  - Bubendorf L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100205
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - DNA, Neoplasm/analysis
MH  - Diagnosis, Differential
MH  - Female
MH  - Genes, p16
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Mesothelioma/genetics/*pathology
MH  - Middle Aged
MH  - Pleural Effusion/diagnosis
MH  - Pleural Effusion, Malignant/genetics/*pathology
MH  - Polymerase Chain Reaction
MH  - Retrospective Studies
EDAT- 2010/02/09 06:00
MHDA- 2010/08/18 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - S0012-3692(10)60358-3 [pii]
AID - 10.1378/chest.09-1951 [doi]
PST - ppublish
SO  - Chest. 2010 Jul;138(1):137-44. doi: 10.1378/chest.09-1951. Epub 2010 Feb 5.